Structural Heart Disease: Definition, Clinical Significance, and Overview

Structural Heart Disease Introduction (What it is)

Structural Heart Disease refers to abnormalities of the heart’s anatomy that affect how blood flows through the heart and great vessels.
It is a clinical domain spanning diagnosis (imaging and hemodynamics) and treatment (medical therapy, catheter-based intervention, and surgery).
The term is commonly used in cardiology, cardiothoracic surgery, echocardiography, and multidisciplinary “heart team” decision-making.
It most often centers on cardiac valves, congenital defects, chambers, and adjacent structures such as the aorta.

Clinical role and significance

Structural Heart Disease matters because anatomic problems in the heart can produce predictable physiologic consequences: pressure overload, volume overload, impaired forward flow, and congestion. These changes drive symptoms and complications that overlap with common syndromes such as heart failure, pulmonary hypertension, and atrial fibrillation (AF).

Clinically, Structural Heart Disease provides a framework for:

• Pathophysiology: linking a lesion (for example, aortic stenosis) to hemodynamic effects (increased left ventricular afterload) and downstream remodeling (hypertrophy, diastolic dysfunction).
• Diagnosis: guiding selection and interpretation of echocardiography (including Doppler), cardiac computed tomography (CT), cardiac magnetic resonance (CMR), and cardiac catheterization.
• Risk stratification: estimating clinical risk based on lesion severity, ventricular function, symptoms, and comorbidities; and informing timing of intervention.
• Intervention planning: choosing between medical therapy, transcatheter therapies (for example, transcatheter aortic valve replacement, TAVR), and surgery (for example, valve repair or replacement).
• Long-term management: monitoring for progression, prosthetic valve function, arrhythmias, and endocarditis risk in selected contexts.

Because many lesions progress over time and can be asymptomatic initially, recognizing Structural Heart Disease early is a core competency for clinicians who interpret murmurs, ECGs, imaging, and heart failure presentations.

Indications / use cases

Structural Heart Disease is discussed or assessed in scenarios such as:

• A new heart murmur or abnormal heart sounds on exam
• Symptoms suggestive of valve disease: exertional dyspnea, reduced exercise tolerance, presyncope/syncope, or angina-like chest discomfort (symptom patterns vary)
• Heart failure (reduced or preserved ejection fraction) where an anatomic lesion may be causal or contributory
• Stroke or systemic embolism evaluation when conditions such as left atrial appendage (LAA) thrombus risk or patent foramen ovale (PFO) are considered
• Adult survivors of congenital heart disease (for example, atrial septal defect, ventricular septal defect, repaired tetralogy of Fallot) needing surveillance
• Infective endocarditis workup or follow-up when valvular destruction, regurgitation, or abscess is suspected
• Preoperative assessment for non-cardiac surgery when known or suspected significant valve disease is present
• Planning for catheter-based structural interventions (for example, TAVR, transcatheter edge-to-edge repair for mitral regurgitation, ASD/PFO closure, LAA occlusion)
• Evaluation of aortic disease (for example, aortic root dilation) that may coexist with valvular or genetic syndromes

Contraindications / limitations

Structural Heart Disease is a broad category rather than a single test or therapy, so “contraindications” apply most directly to specific diagnostic modalities and interventions. Key limitations and situations where another approach may be better include:

• Terminology limitations: not all cardiac conditions are “structural” (for example, primary electrical disorders without anatomic disease), and some entities overlap (for example, cardiomyopathy has both structural and functional components).
• Imaging constraints: transthoracic echocardiography (TTE) can be limited by body habitus or lung disease; transesophageal echocardiography (TEE) is semi-invasive and may be limited by esophageal pathology.
• CT/CMR constraints: CT involves ionizing radiation and iodinated contrast; CMR may be limited by certain implants, severe claustrophobia, or inability to cooperate with breath-holding (varies by device and institution).
• Intervention constraints: transcatheter and surgical interventions may not be suitable in some anatomic patterns (for example, unfavorable valve morphology) or in patients whose overall risk profile makes benefit uncertain (varies by clinician and case).
• Hemodynamic ambiguity: some lesions are dynamic or load-dependent (for example, functional mitral regurgitation), so severity estimates can change with blood pressure, volume status, and rhythm.

How it works (Mechanism / physiology)

Structural Heart Disease is defined by anatomic change; it does not have a “mechanism of action” like a drug. Instead, it has physiologic mechanisms that explain symptoms, exam findings, and imaging results.

Core physiologic principles

• Stenosis (obstruction): a narrowed valve or outflow tract increases resistance to flow, creating a pressure gradient and pressure overload. Classic examples include aortic stenosis and pulmonary stenosis.
• Regurgitation (leak): an incompetent valve allows backward flow, producing volume overload and chamber dilation over time. Examples include mitral regurgitation and aortic regurgitation.
• Shunts: abnormal connections (for example, ASD, VSD, PDA) redirect blood between chambers or vessels. The direction and magnitude depend on relative pressures and vascular resistance.
• Obstructive cardiomyopathies and anatomic variants: structures such as the interventricular septum or subvalvular apparatus can obstruct flow (for example, hypertrophic obstructive cardiomyopathy involves both myocardial structure and dynamic physiology).
• Aortic and great vessel disease: dilation, aneurysm, or coarctation alters afterload and flow patterns, with downstream ventricular remodeling.

Relevant anatomy and structures

Structural Heart Disease commonly involves:

• Valves: aortic, mitral, tricuspid, pulmonary; including leaflets, annulus, chordae tendineae, papillary muscles
• Myocardium and chambers: left ventricle (LV), right ventricle (RV), atria; remodeling, hypertrophy, and dilation
• Septal structures: interatrial septum, interventricular septum (including defects and aneurysms)
• Great vessels: aorta, pulmonary artery; aortic root and ascending aorta
• Conduction-adjacent anatomy: while arrhythmias are electrical, structural changes (atrial enlargement, scar, valve calcification) can predispose to AF or conduction disease

Onset, duration, and reversibility

Structural lesions may be congenital (present at birth) or acquired (degenerative calcification, rheumatic disease, endocarditis, ischemic remodeling). Many are chronic and progressive, though the rate of progression varies by lesion and patient factors. Some physiologic consequences (congestion, elevated filling pressures) can improve with medical therapy, while the underlying anatomy may require repair or replacement to change the natural course.

Structural Heart Disease Procedure or application overview

Structural Heart Disease is applied clinically through a structured assessment and treatment pathway rather than a single procedure. A typical high-level workflow is:

1. Evaluation / exam
   – Symptom review (dyspnea, fatigue, chest discomfort, syncope, palpitations) and functional capacity
   – Cardiac exam (murmur timing/quality, signs of volume overload)
   – Baseline ECG and labs as clinically indicated

2. Diagnostics
   – Transthoracic echocardiography (TTE): first-line for valve anatomy, gradients, regurgitation severity, ventricular size/function
   – Transesophageal echocardiography (TEE): when more detail is needed (for example, endocarditis evaluation, mitral valve morphology, interatrial septum assessment)
   – Cardiac CT: annular sizing and vascular access planning for some transcatheter interventions; assessment of aortic and valve calcification
   – CMR: ventricular volumes, flow quantification, tissue characterization in selected cardiomyopathies and congenital disease
   – Cardiac catheterization: coronary assessment when relevant; direct hemodynamic measurements when noninvasive findings are discordant or when planning intervention

3. Preparation / planning
   – Multidisciplinary discussion (often a structural “heart team” including interventional cardiology, cardiac surgery, imaging, anesthesia, and nursing)
   – Review of anatomy, procedural feasibility, comorbidities, frailty, and patient goals (varies by clinician and case)

4. Intervention / testing (when indicated)
   – Options include medical optimization, transcatheter repair/replacement, surgical repair/replacement, or surveillance
   – Procedural approach and anesthesia strategy depend on lesion, anatomy, and institutional practice (varies by case)

5. Immediate checks
   – Post-procedure imaging or hemodynamic assessment for residual regurgitation/gradient, ventricular function, and complications as appropriate
   – Rhythm monitoring for conduction disturbances or atrial arrhythmias in selected settings

6. Follow-up / monitoring
   – Serial clinical assessment and repeat imaging at intervals tailored to lesion severity, intervention type, and symptoms (intervals vary by clinician and case)
   – Long-term monitoring for prosthetic valve function, recurrence of regurgitation, ventricular remodeling, and endocarditis risk education in relevant patients

Types / variations

Structural Heart Disease includes a broad set of entities that can be organized in clinically useful ways.

By anatomic category

• Valvular heart disease
• Stenosis: aortic stenosis, mitral stenosis (often rheumatic), pulmonic stenosis
• Regurgitation: mitral regurgitation (primary/degenerative vs secondary/functional), aortic regurgitation, tricuspid regurgitation
• Congenital heart disease (CHD)
• Shunts: ASD, VSD, PDA, PFO (anatomic variant with clinical relevance in selected contexts)
• Complex lesions: repaired tetralogy of Fallot, transposition repairs, single-ventricle pathways
• Aortic and great vessel disease
• Bicuspid aortic valve–associated aortopathy, aortic root dilation, coarctation of the aorta
• Cardiomyopathies with structural remodeling
• Dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive phenotypes (overlap with “structural” and “myocardial” classifications)

By time course and presentation

• Acute: papillary muscle rupture after myocardial infarction causing acute severe mitral regurgitation; endocarditis with acute valve destruction; acute aortic syndromes involving the root
• Chronic: degenerative calcific aortic stenosis; chronic functional mitral regurgitation in LV dysfunction; progressive tricuspid regurgitation with right-sided dilation

By functional impact

• Obstructive lesions (pressure overload) vs regurgitant lesions (volume overload) vs shunt lesions (recirculation and chamber overload)
• Compensated (remodeling maintains output) vs decompensated (symptoms, congestion, or declining ventricular function)

By management strategy

• Medical management and surveillance (symptom control, blood pressure optimization, rhythm management)
• Transcatheter therapies (TAVR; transcatheter mitral/tricuspid repair in selected cases; ASD/PFO closure; LAA occlusion)
• Surgical therapies (valve repair or replacement; congenital repairs; aortic surgery)

Advantages and limitations

Advantages:

• Clarifies disease mechanisms by linking anatomy to hemodynamics (pressure/volume overload, shunts).
• Provides a shared language for multidisciplinary care (cardiology, imaging, surgery, anesthesia).
• Anchors diagnostic strategies around high-yield tools like echocardiography and Doppler assessment.
• Supports risk stratification using lesion severity, ventricular response, and symptoms.
• Helps organize management pathways (surveillance vs intervention; transcatheter vs surgical).
• Encourages longitudinal follow-up for progressive lesions and post-intervention surveillance.

Limitations:

• The term is broad and can be imprecise without specifying the lesion (for example, “structural disease” does not equal “valve disease” in every case).
• Severity assessment can be load- and rhythm-dependent, especially for functional regurgitation.
• Imaging windows and modality limitations can restrict accuracy in some patients.
• Management decisions often depend on patient-specific factors (frailty, comorbidities, anatomy), so general rules have exceptions (varies by clinician and case).
• Transcatheter and surgical therapies require specialized expertise and resources that vary by institution.
• Some symptoms attributed to structural lesions may be multifactorial (lung disease, anemia, deconditioning), complicating attribution.

Follow-up, monitoring, and outcomes

Outcomes in Structural Heart Disease are influenced by the type of lesion, severity, and the heart’s physiologic response (ventricular size and function, pulmonary pressures, rhythm). Monitoring typically combines symptom tracking with repeat imaging to detect progression or post-intervention changes.

Common factors that affect monitoring and outcomes include:

• Baseline ventricular function and remodeling: LV ejection fraction, chamber size, RV function, and atrial enlargement.
• Hemodynamics: gradients, regurgitant severity, filling pressures, and pulmonary hypertension when present.
• Rhythm status: AF and other arrhythmias can worsen symptoms and complicate regurgitation assessment.
• Comorbidities: coronary artery disease, chronic kidney disease, chronic lung disease, diabetes, and frailty can affect procedural candidacy and recovery.
• Adherence and access to follow-up: consistent surveillance and timely reassessment when symptoms change.
• Rehabilitation and functional recovery: participation in supervised programs may be considered after some interventions (varies by institution and patient).
• Device/material considerations: durability and follow-up requirements differ among prostheses and repair techniques (varies by device, material, and institution).

Clinicians often frame follow-up around “red flags” for reassessment (new dyspnea, syncope, edema, declining exercise tolerance) and objective changes on imaging.

Alternatives / comparisons

Because Structural Heart Disease is a category, “alternatives” refer to different management strategies for a given lesion rather than substitutes for the diagnosis.

• Observation / surveillance vs intervention
• Mild or asymptomatic lesions may be monitored with periodic clinical review and echocardiography.

• Intervention is considered when lesion severity and symptoms (or ventricular changes) suggest meaningful risk from continued progression; thresholds vary by lesion and guidelines.

• Medical therapy vs anatomic correction

• Medications can reduce congestion, control blood pressure, and manage arrhythmias, improving physiology without directly correcting valve anatomy.

• Repair or replacement targets the anatomic problem but introduces procedural considerations and long-term surveillance needs.

• Transcatheter vs surgical approaches

• Transcatheter therapies can offer less invasive options for selected patients and anatomies.

• Surgery may be favored when complex repair is needed, when multiple lesions require correction, or when anatomy is not suitable for a transcatheter approach. Suitability varies by clinician and case.

• Device therapy vs rhythm/medical management

• Some patients with structural disease and heart failure may be evaluated for device therapy (for example, cardiac resynchronization therapy) when conduction abnormalities and ventricular dysfunction coexist.
• Others may benefit primarily from guideline-directed medical therapy for heart failure and targeted lesion management.

A balanced approach typically integrates symptom burden, lesion severity, anatomy, procedural feasibility, and patient-centered goals.

Structural Heart Disease Common questions (FAQ)

Q: Does Structural Heart Disease always cause chest pain or shortness of breath?
No. Some lesions are asymptomatic for years and are found incidentally on exam or echocardiography. Symptoms depend on lesion type, severity, rate of progression, and the heart’s compensatory response.

Q: Is Structural Heart Disease the same as coronary artery disease?
Not exactly. Coronary artery disease primarily involves atherosclerotic narrowing of coronary arteries, while Structural Heart Disease centers on valves, chambers, septa, and great vessels. They can coexist, and coronary assessment is often relevant when planning interventions.

Q: How is Structural Heart Disease diagnosed?
Diagnosis typically starts with history, physical exam, and transthoracic echocardiography (TTE). Depending on the question, clinicians may add transesophageal echocardiography (TEE), cardiac CT, CMR, or cardiac catheterization to clarify anatomy and hemodynamics.

Q: If an intervention is needed, will it require general anesthesia?
It depends on the procedure, patient factors, and institutional practice. Some transcatheter procedures may use monitored anesthesia care or general anesthesia, while most open surgical procedures use general anesthesia. The plan varies by clinician and case.

Q: Is treatment “safe”?
All evaluations and interventions carry potential risks, which differ by lesion, procedure type, and patient comorbidities. Risk assessment is individualized and commonly discussed in a multidisciplinary setting for complex valve and congenital decisions.

Q: How long do the results of valve repair or replacement last?
Durability depends on the underlying disease, repair technique, and the type of prosthetic valve or device (varies by device, material, and institution). Ongoing follow-up is used to detect degeneration, dysfunction, or recurrent regurgitation.

Q: Will I have pain after a procedure for Structural Heart Disease?
Discomfort varies widely by approach. Catheter-based procedures often involve access-site soreness, while surgical procedures typically involve more postoperative pain due to incisions and healing. Pain management strategies differ by institution and patient factors.

Q: What is the cost range for Structural Heart Disease testing or treatment?
Costs vary substantially by country, healthcare system, imaging modality, length of stay, device selection, and insurance coverage. In practice, billing and coverage are best addressed through institutional financial counseling rather than clinical estimates.

Q: Are there activity restrictions with Structural Heart Disease?
Restrictions depend on lesion severity, symptoms, ventricular function, and rhythm status. Clinicians often individualize guidance around exertion, competitive sports, and rehabilitation plans (varies by clinician and case).

Q: How often is follow-up imaging needed?
Follow-up intervals depend on the specific lesion, its severity, symptom trajectory, and whether an intervention has occurred. Mild disease may be followed less frequently than severe or rapidly changing disease, and post-procedure surveillance schedules vary by device and institution.